^
    1year
    Multi-omics analysis reveals CLIC1 as a therapeutic vulnerability of gliomas. (PubMed, Front Pharmacol)
    High CLIC1 expression samples were more sensitive to camptothecin, cisplatin, doxorubicin, erlotinib, paclitaxel, rapamycin, clofarabine, tanespimycin, methotrexate, everolimus, TAK-733, trametinib and AZD8330. Single-cell analysis unveiled that CLIC1 was expressed ubiquitously in tumor cells and tumor microenvironment. Overall, CLIC1 was a promising treatment vulnerability in glioma.
    Journal
    |
    CLIC1 (Chloride Intracellular Channel 1)
    |
    IDH wild-type
    |
    Mekinist (trametinib) • cisplatin • erlotinib • paclitaxel • everolimus • doxorubicin hydrochloride • methotrexate • sirolimus • clofarabine • tanespimycin (BMS-722782) • REC-4881 • AZD8330
    over4years
    B7-H6 Promotes Cell Proliferation, Migration and Invasion of Non-Hodgkin Lymphoma via Ras/MEK/ERK Pathway Based on Quantitative Phosphoproteomics Data. (PubMed, Onco Targets Ther)
    Strikingly, MEK inhibitor AZD8330 was found to have the ability to sufficiently inhibit Ras/MEK/ERK pathway, partially reverse cell proliferation and completely reverse cell migration and invasion induced by B7-H6. B7-H6 promotes cell proliferation, migration and invasion in NHL via Ras/MEK/ERK pathway. Hence, B7-H6 or Ras/MEK/ERK pathway targeting may be used as potential therapeutics for treating NHL.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    AZD8330